{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:57:11Z","timestamp":1774339031146,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ijantimicag.2018.10.012","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T07:26:56Z","timestamp":1540798016000},"page":"275-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation"],"prefix":"10.1016","volume":"53","author":[{"given":"M. Tobias","family":"Heinrichs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Drusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-9130","authenticated-orcid":false,"given":"Sherwin K.B.","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth H.","family":"Rand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Derendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0001","unstructured":"World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant bacterial infections, including tuberculosis. WHO\/EMP\/IAU\/2017.12. 2017."},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0002","series-title":"Global tuberculosis report 2016","year":"2016"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0003","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/2047-783X-15-12-533","article-title":"Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin","volume":"15","author":"Estes","year":"2010","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01741-15","article-title":"Preclinical Evaluations to identify optimal linezolid regimens for tuberculosis therapy","volume":"6","author":"Brown","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00226-17","article-title":"Lung tissue concentrations of pyrazinamide among patients with drug-resistant pulmonary tuberculosis","volume":"61","author":"Kempker","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0007","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000342423","article-title":"Impact of pH on activity of trimethoprim, fosfomycin, amikacin, colistin and ertapenem in human urine","volume":"90","author":"Burian","year":"2012","journal-title":"Pharmacology"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0008","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0009","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/jam.12241","article-title":"Effect of pH on the in vitro susceptibility of planktonic and biofilm-grown Proteus mirabilis to the quinolone antimicrobials","volume":"115","author":"Irwin","year":"2013","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0010","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs","volume":"53","author":"Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0011","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/jac\/dkx421","article-title":"Moxifloxacin Target site concentrations in patients with pulmonary tuberculosis utilizing microdialysis: a clinical pharmacokinetic study","volume":"73","author":"Heinrichs","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0012","series-title":"Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes: approved standard [NCCLS document M24- A.2003]","year":"2003"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0013","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1128\/JCM.38.4.1498-1501.2000","article-title":"New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide","volume":"38","author":"Heifets","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0014","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1128\/AAC.38.6.1386","article-title":"Effect of 2\u2019,3\u2019-didehydro-3\u2019-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies","volume":"38","author":"Bilello","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0015","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1753465815620338","article-title":"Pharmacokinetics of consecutive oral moxifloxacin (400 mg\/day) in patients with respiratory tract infection","volume":"10","author":"Ito","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0017","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1128\/AAC.01378-08","article-title":"Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis","volume":"53","author":"McGee","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0018","unstructured":"U.S. Food and Drug Administration. NDA 21-085 Avelox Clinical Pharmacology and Biopharmaceutics Review. 1998."},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0019","first-page":"435","article-title":"Oxazolidinones: a new class of antimicrobials","volume":"16","author":"Ford","year":"1999","journal-title":"Infect Med"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0020","series-title":"Proceedings of the 14th IEEE Symposium on Computer- Based Medical Systems","first-page":"389","article-title":"An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK\/PD) population models","author":"Leary","year":"2001"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0021","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/0091270009337947","article-title":"Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients","volume":"49","author":"Abe","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0022","unstructured":"EUCAST database. www.eucast.org\/."},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2018.10.012_bib0023","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1093\/cid\/civ426","article-title":"Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2018.10.012_bib0024","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/cid\/civ424","article-title":"Strategic regulatory evaluation and endorsement of the hollow fiber tuberculosis system as a novel drug development tool","volume":"61","author":"Romero","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0025","doi-asserted-by":"crossref","first-page":"i843","DOI":"10.1136\/bmj.i843","article-title":"Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study","volume":"352","author":"Inghammar","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0026","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/AAC.41.5.1004","article-title":"Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium","volume":"41","author":"Collins","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0027","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1128\/IAI.66.2.794-799.1998","article-title":"Growth of virulent and avirulent Mycobacterium tuberculosis strains in human macrophages","volume":"66","author":"Zhang","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.ijantimicag.2018.10.012_bib0028","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/ijmy.ijmy_33_18","article-title":"Mycobacterium tuberculosis strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs","volume":"7","author":"Heinrichs","year":"2018","journal-title":"Int J Mycobacteriol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T06:01:11Z","timestamp":1605333671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918303042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0924857918303042"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.012","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}